New hope for HER2-Mutant lung cancer: phase 3 trial launches
NCT ID NCT07178795
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 3 trial is testing a new drug called BL-M07D1 against standard chemotherapy (pembrolizumab plus platinum chemo) as a first treatment for people with advanced or metastatic non-squamous non-small cell lung cancer that has a HER2 mutation. About 440 participants will be randomly assigned to receive either the new drug or standard therapy. The main goal is to see if BL-M07D1 can delay cancer growth or improve survival.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
BL-M07D1 (a drug given by IV every 3 weeks)
What this could lead to
If it works, this could offer a new first-line treatment option for people with a specific type of advanced lung cancer that has a HER2 mutation.
What could go wrong
This is an early Phase 3 trial, so results are not yet known. The new drug may not be more effective than current standard therapy and could have unexpected side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SQUAMOUS NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Sun Yat-sen University Cancer Center
RECRUITINGGuangzhou, Guangdong, China
Contact